Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Increases Proposed Offering of Stock to $50M

NEW YORK (GenomeWeb News) – Cancer Genetics today increased the proposed amount it is seeking to raise from a public offering of its common stock.

In an amended Form S-1, the Rutherford, NJ-based cancer diagnostics firm said that it plans to offer $50 million of its common shares. When the company announced the offering earlier this month, it said that the proposed maximum aggregate offering price would be $46 million.

The company has not said how many shares it plans to offer.

Aegis Capital is the sole book-running manager, and Feltl & Co., Cantor Fitzgerald, and Dougherty & Co., are co-managers on the offering. Cancer Genetics is granting the underwriters a 45-day option to purchase up to $7.5 million of additional shares of its common stock to cover any overallotments, which could potentially bring the total amount raised to $57.5 million.

It said that net proceeds from the offering are expected to be about $45.9 million, or $52.9 million if the underwriters exercise their overallotment option in full.

Cancer Genetics made a public offering of $15 million of its shares in August, when it also began trading on the Nasdaq. The company went public in April.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.